GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kingworld Medicines Group Ltd (HKSE:01110) » Definitions » Forward PE Ratio

Kingworld Medicines Group (HKSE:01110) Forward PE Ratio : 0.00 (As of Jun. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Kingworld Medicines Group Forward PE Ratio?

Kingworld Medicines Group's Forward PE Ratio for today is 0.00.

Kingworld Medicines Group's PE Ratio without NRI for today is 10.75.

Kingworld Medicines Group's PE Ratio for today is 8.03.


Kingworld Medicines Group Forward PE Ratio Historical Data

The historical data trend for Kingworld Medicines Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kingworld Medicines Group Forward PE Ratio Chart

Kingworld Medicines Group Annual Data
Trend
Forward PE Ratio

Kingworld Medicines Group Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Kingworld Medicines Group's Forward PE Ratio

For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kingworld Medicines Group's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Kingworld Medicines Group's Forward PE Ratio falls into.



Kingworld Medicines Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Kingworld Medicines Group  (HKSE:01110) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Kingworld Medicines Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Kingworld Medicines Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kingworld Medicines Group (HKSE:01110) Business Description

Traded in Other Exchanges
N/A
Address
198 Daxin Road, 8th-9th Floor, Block A, Majialong Chuangxin Building, Nanshan District, Guangdong Province, Shenzhen, CHN, 518016
Kingworld Medicines Group Ltd is engaged in Distribution sales of pharmaceutical and healthcare products such as branded imported pharmaceutical and healthcare products primarily in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices primarily carried out in the PRC. It derives the majority of its revenue from Distribution sales of pharmaceutical and healthcare products segment.
Executives
Chan Lok San 2101 Beneficial owner
Zhao Li Sheng 2101 Beneficial owner
Sinopharm Capital Limited 2201 Interest of corporation controlled by you
Sinopharm Healthcare Fund L.p. 2101 Beneficial owner
Sun Hill Capital Investments Limited 2201 Interest of corporation controlled by you
Wu Aimin 2201 Interest of corporation controlled by you
Sun Hill Capital Investments Limited 2201 Interest of corporation controlled by you
Wu Aimin 2201 Interest of corporation controlled by you

Kingworld Medicines Group (HKSE:01110) Headlines

No Headlines